Phocas Financial Corp’s Acadia Pharmaceuticals ACAD Stock Holding History

Phocas Financial Corp’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.95M	Sell	77,245 -4,102	-5%	-$90.3K	0.27%	116
2026 Q1	$1.81M	Sell	81,347 -22,725	-22%	-$543K	0.28%	114
2025 Q4	$2.78M	Sell	104,072 -271	-0.3%	-$6.48K	0.36%	101
2025 Q3	$2.23M	Buy	104,343 +2,167	+2%	+$51.2K	0.29%	109
2025 Q2	$2.2M	Buy	102,176 +15	+0%	+$279	0.32%	100
2025 Q1	$1.7M	Sell	102,161 -5,650	-5%	-$103K	0.26%	107
2024 Q4	$1.98M	Buy	+107,811	New	+$1.74M	0.26%	112
2023 Q4	$2.1M	Buy	66,957 +1,266	+2%	+$30.2K	0.28%	115
2023 Q3	$1.37M	Buy	+65,691	New	+$1.78M	0.2%	120

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Phocas Financial Corp's ACAD Position: Q2 2026 in Review

Phocas Financial Corp reduced its Acadia Pharmaceuticals (ACAD) stake by 5% in Q2 2026, selling an estimated $90.3K and leaving 77,245 shares worth $1.95M. The position accounts for 0.27% of the portfolio, ranked #116.

Phocas Financial Corp first reported a position in ACAD in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.78M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Phocas Financial Corp held 77,245 shares of Acadia Pharmaceuticals worth $1.95M as of Q2 2026.
Phocas Financial Corp sold 4,102 Acadia Pharmaceuticals shares in Q2 2026, an estimated $90.3K.
Acadia Pharmaceuticals made up 0.27% of Phocas Financial Corp's portfolio in Q2 2026, its #116 holding.
Phocas Financial Corp first reported a position in Acadia Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Phocas Financial Corp's Acadia Pharmaceuticals position peaked at $2.78M in Q4 2025.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.